Incidence and clinical characteristics of gastroenteropancreatic neuroendocrine tumor in Korea: a single-center experience
- PMID: 28490723
- PMCID: PMC5432789
- DOI: 10.3904/kjim.2015.232
Incidence and clinical characteristics of gastroenteropancreatic neuroendocrine tumor in Korea: a single-center experience
Abstract
Background/aims: Neuroendocrine tumors (NETs) may originate from heterogeneous neuroendocrine cells. The incidence is increasing worldwide, and World Health Organization (WHO) updated its classification in 2010. We investigated clinical characteristics of gastroenteropancreatic NETs in a single center.
Methods: Clinicopathologic characteristics of patients with pathologically confirmed gastroenteropancreatic NET in Seoul St. Mary Hospital from March 2009 to August 2011 were retrospectively analyzed. The grade and stage were determined according to WHO 2010 classification and TNM Staging System for Neuroendocrine Tumors (7th ed., 2010) of American Joint Committee on Cancer.
Results: One hundred and twenty-five patients (median age, 50; male, 61.3%) were analyzed. Among 100,000 patients who visited the hospital, incidence was 24.1. Only two patients (1.6%) had a functional NET. The rectum (n = 99, 79.8%) was most common primary site and found in early stage. The prevalence by stages was 84.7% stage I, 8.9% stage IV, 4.8% stage II, and 1.6% stage III. The pathology grading was 74.5% grade 1, 12.7% grade 2, and 12.7% grade 3. Tumor stage correlated positively with pathologic grade (Spearman's rank correlation coefficient, 0.644).
Conclusions: Wide range of clinicopathological features of Korean gastroenteropancreatic NETs were demonstrated using WHO 2010 classification. Rectal NET was most frequent and found in early stage.
Keywords: Epidemiology; Gastro-enteropancreatic neuroendocrine tumor; Incidence; Neuroendocrine tumors; Survival.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Similar articles
-
Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.Cancer. 2008 Jul 15;113(2):256-65. doi: 10.1002/cncr.23549. Cancer. 2008. PMID: 18506737
-
Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.Eur J Gastroenterol Hepatol. 2016 Jul;28(7):836-41. doi: 10.1097/MEG.0000000000000619. Eur J Gastroenterol Hepatol. 2016. PMID: 26945127
-
Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.Virchows Arch. 2007 Aug;451 Suppl 1:S9-27. doi: 10.1007/s00428-007-0461-0. Epub 2007 Aug 8. Virchows Arch. 2007. PMID: 17684761 Review.
-
Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.Turk J Gastroenterol. 2016 Nov;27(6):509-514. doi: 10.5152/tjg.2016.16391. Turk J Gastroenterol. 2016. PMID: 27852541
-
Gastroenteropancreatic (neuro)endocrine neoplasms: the histology report.Dig Liver Dis. 2011 Mar;43 Suppl 4:S356-60. doi: 10.1016/S1590-8658(11)60591-4. Dig Liver Dis. 2011. PMID: 21459341
Cited by
-
Classification and Locoregional Treatment of Rectal Neuroendocrine Tumors.Cureus. 2023 Jun 8;15(6):e40128. doi: 10.7759/cureus.40128. eCollection 2023 Jun. Cureus. 2023. PMID: 37425523 Free PMC article.
-
Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation?Curr Oncol Rep. 2022 Mar;24(3):257-263. doi: 10.1007/s11912-021-01172-1. Epub 2022 Jan 27. Curr Oncol Rep. 2022. PMID: 35084662 Free PMC article. Review.
-
Clinical analysis of 547 patients with neuroendocrine tumors in a Chinese population: A single-center study.Cancer Med. 2019 Jul;8(8):3729-3737. doi: 10.1002/cam4.2259. Epub 2019 May 24. Cancer Med. 2019. PMID: 31127690 Free PMC article.
-
Clinicopathological Findings and Treatment Outcomes of Patients with Primary Hepatobiliary Neuroendocrine Neoplasms: A Retrospective Single-institution Analysis.Intern Med. 2024 Apr 1;63(7):891-901. doi: 10.2169/internalmedicine.2016-23. Epub 2023 Aug 23. Intern Med. 2024. PMID: 37612088 Free PMC article.
-
Current advances in neuroendocrine neoplasms of the colon and rectum.World J Clin Oncol. 2025 Aug 24;16(8):108906. doi: 10.5306/wjco.v16.i8.108906. World J Clin Oncol. 2025. PMID: 40901326 Free PMC article. Review.
References
-
- Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072. - PubMed
-
- Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25:5609–5615. - PubMed
-
- Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113:2655–2664. - PubMed
-
- Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45:234–243. - PubMed
-
- Oberg K. Expression of growth factors and their receptors in neuroendocrine gut and pancreatic tumors, and prognostic factors for survival. Ann N Y Acad Sci. 1994;733:46–55. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources